SMC Spain

SMC Spain

SMC Spain
Position
Topics

New drug improves narcolepsy symptoms, clinical trial shows

Narcolepsy type 1 is a sleep disorder characterised by excessive daytime sleepiness and cataplexy - sudden loss of muscle tone. Existing treatments are based on palliation of symptoms, with moderate success. Now, an international phase 2 clinical trial, involving CEU San Pablo University and other Spanish centres, published in the journal NEJM, shows the results of a new drug targeting the cause of the disorder. Overall, the benefits appear superior and no serious adverse effects were observed. According to the authors, ‘the results are promising’ and represent ‘a very significant impact on the quality of life of these patients’.

0

Oral norovirus vaccine shows positive results in phase 2 clinical trial

According to the results of a phase 2 trial, an oral norovirus vaccine generated a strong mucosal immune response and even reduced viral shedding in vaccinated volunteers. Signs of the vaccine's efficacy support its potential to address the lack of safe and reliable vaccines against this virus, which is a major cause of gastrointestinal infections worldwide. The results were published today in the journal Science Translational Medicine.

0

A drug reduces the symptoms that precede migraine in a phase III trial

A migraine treatment drug, ubrogepant, also reduces common non-headache symptoms that occur in the hours before a migraine, according to the results of a large phase III clinical trial published in Nature Medicine. The results suggest that this could be the first acute treatment for symptoms that occur before migraine and have a significant impact on daily life, such as dizziness, sensitivity to light and noise, and neck pain.

0

Design DNA fragments that control genes in mammalian cells with AI

A team from the Centre for Genomic Regulation (CRG) and Pompeu Fabra University (UPF) in Barcelona has developed an artificial intelligence tool capable of designing regulatory sequences for genes that do not exist in nature. When introduced into cells, these enhancers can increase or decrease gene activity in a specific way depending on the type of cell targeted. According to the authors, ‘the potential applications are enormous. It's like writing software, but for biology.’ The results are published in the journal Cell.

0

Nearly one in five women and one in seven men have experienced sexual violence before the age of 18 worldwide

Research published in The Lancet estimates that 18.9% of women and 14.8% of men worldwide experienced sexual violence before the age of 18. The study, conducted in 204 countries from 1990 to 2023, identified significant differences between countries and regions. The authors highlight the difficulty of distinguishing whether these variations are due to real differences or to unequal levels of reporting. In Spain, the figures obtained in this systematic review are 10.8% for girls and 12.2% for boys. 

0

Phase 1 trial tests “weaponized” CAR-T cell therapy to improve lymphoma response

A phase 1 clinical trial has tested the safety and preliminary efficacy of a new form of CAR-T cell therapy - which they call “armed” - in patients with lymphoma. The novelty consists of adding another gene to help increase response. Of the 21 patients treated, all resistant to multiple lines of treatment including approved CAR-T therapies in 20 of them, 81% showed a response and 52% went on to achieve complete remission without significantly greater side effects than with the standard option. The results are published in the journal NEJM.  

0

Study suggests eating ultra-processed foods may accelerate early Parkinson's symptoms

Consumption of ultra-processed food is associated with an increased likelihood of having prodromal signs of Parkinson's disease - symptoms that precede the disease - says a study published in Neurology. The analysis is based on data from more than 42,000 healthcare professionals in the US, followed for up to 26 years.

0

Teenagers with mental health problems spend more time on social media, UK study finds

A team has analysed data from a survey of more than 3,000 teenagers aged 11-19 in the UK. Their findings show that those with mental health problems spend an average of 50 minutes more per day on social media than those who do not suffer from them. According to the authors, who publish the results in the journal Nature Human Behaviour, further research is needed to know if this is a causal relationship.

0